Should You Buy Prestige Consumer Healthcare Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare Inc. (PBH) scores a robust 8.3/10 on our 32-signal Quality of Company framework. At the current market price of $46.68 and a $2.2B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 8 of 12 CirclFi valuation models project upside for Prestige Consumer Healthcare Inc. (PBH) at $46.68 — the model consensus leans bullish, with a Quality Score of 8.3/10 and Value-Trap risk of 20/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Prestige Consumer Healthcare Inc. (PBH) in 2026?
What Is the Bull Case vs the Bear Case for Prestige Consumer Healthcare Inc. (PBH)?
| Bull case — $113.57 target (+143.3%) | Bear case — $23.22 target (-50.3%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Prestige Consumer Healthcare Inc.'s quality score of 8.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $23.22 (-50.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $46.68 and the median fair value of $76.29 implies +63.4% upside potential. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +193.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $113.57 (+143.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: clinical trial failure represents a meaningful risk for Prestige Consumer Healthcare Inc. and its Drug Manufacturers - Specialty & Generic peers. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Prestige Consumer Healthcare Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. |
How Does PBH Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: SIGA · AMRX · BCRX · KNSA · ETST · ORGO · CPIX · YCBD · RDHL · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like PBH on Quality?
Closest companies to PBH’s Quality of Company score of 8.3/10, across all industries.
- NKE — NIKE, Inc. (QOC 8.3) · analysis
- MFG — Mizuho Financial Group, Inc. (QOC 8.3) · analysis
- IQV — IQVIA Holdings Inc. (QOC 8.3) · analysis
- UDR — UDR, Inc. (QOC 8.3) · analysis
- TBBK — The Bancorp, Inc. (QOC 8.3) · analysis
- HAL — Halliburton Company (QOC 8.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does PBH Appear In?
So Is Prestige Consumer Healthcare Inc. (PBH) Worth Buying in 2026?
Prestige Consumer Healthcare Inc. leans positive in our analysis — 7/12 models bullish, median fair value of $76.29 vs. $46.68, QOC 8.3/10. The case is constructive but not overwhelming, and the 4 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Prestige Consumer Healthcare Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PBH Stock?
Should I buy PBH stock right now?
Based on CirclFi's multi-model analysis, 8 of 12 models see upside for PBH at $46.68. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Prestige Consumer Healthcare Inc.?
Key risks include: wide model disagreement (389% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does PBH compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, PBH holds a Quality Score of 8.3/10. Comparable companies include SIGA (QOC 8.4), AMRX (QOC 8.3), BCRX (QOC 8.4). The relative ranking helps investors identify whether PBH offers better fundamental quality than alternatives in the same sector.
Is PBH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PBH's Quality Score of 8.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy PBH at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $23.22 to $113.57. At $46.68, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PBH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad